# EDGAR Filing Document

**Accession Number:** 0001658247
**File Stem:** 0001658247-26-000014
**Filing Date:** 2026-2
**Character Count:** 23969
**Document Hash:** 93aa59763b696f79d1faa01f81ce66d5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001658247-26-000014.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001658247-26-000014

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Crinetics Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001658247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263744114
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293803
- **FILM NUMBER:** 26689579

**BUSINESS ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-450-6464

**MAIL ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**As filed with the Securities and Exchange Commission on February 26, 2026**

**Registration No. 333-**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER** 

**THE SECURITIES ACT OF 1933**

**CRINETICS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **Delaware** | **26-3744114** |
| (State or Other Jurisdiction | (I.R.S. Employer Identification No.) |
| of Incorporation or Organization) | |

---

**6055 Lusk Boulevard**

**San Diego, California 92121**

(Address of principal executive offices) (Zip code)

**Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan**

(Full title of the plan)

**R. Scott Struthers**

**President and Chief Executive Officer** 

**Crinetics Pharmaceuticals, Inc.**

**6055 Lusk Boulevard**

**San Diego, California 92121** 

**(885) 450-6464**

(Name, address, and telephone number, including area code, of agent for service)

***Copies to:*** 

---

| | |
|:---|:---|
| **James Krenn, Esq.<br>Morrison & Foerster LLP<br>12531 High Bluff Drive<br>San Diego, CA 92130<br>(858) 720-5100** | **G. Scott Lesmes, Esq.<br>Emily K. Beers, Esq.<br>Morrison & Foerster LLP<br>2100 L Street NW, Suite 900<br>Washington, D.C. 20037<br>(202) 887-1500** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | |
|:---|:---|
| Large accelerated filer 🗷 | Accelerated filer ◻ |
| Non-accelerated filer ◻ | Smaller reporting company ◻ |
| | Emerging growth company ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**Proposed sales to take place as soon after the effective date of the Registration Statement as awards granted under the above-named plan are granted, exercised and/or distributed.**

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 4,778,774 shares of common stock of Crinetics Pharmaceuticals, Inc. (the "Registrant") issuable or which may become issuable under the Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan (the "2018 Plan") pursuant to the evergreen provisions of such plan.

Pursuant to General Instruction E of Form S-8, the contents of the prior registration statements on Form S-8, File No. 333-226234, File No. 333-254883, File No. 333-264005, File No. 333-270125, File No. 333-277484 and File No. 333-285342, previously filed with respect to the 2018 Plan, are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*In this Registration Statement, Crinetics Pharmaceuticals, Inc. is sometimes referred to as "Registrant," "we," "us" or "our."*

**Item 3. Incorporation of Documents by Reference**

The Securities and Exchange Commission ("SEC") allows us to "incorporate by reference" the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Registrant's Annual Report on Form <u>[10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001658247/000165824726000012/crnx-20251231.htm)</u> for the year ended December 31, 2025, filed with the SEC on February 26, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Registrant's Current Reports on Form 8-K filed with the SEC on <u>[January 5, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001658247/000119312526002368/d86003d8k.htm)</u>, <u>[January 7, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001658247/000119312526006421/d22132d8k.htm)</u> and <u>[January 26, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001658247/000165824726000003/crnx-20260120.htm)</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The description of the Registrant's common stock set forth in the Registrant's registration statement on <u>[Form 8-A12B](https://www.sec.gov/Archives/edgar/data/1658247/000119312518216421/d482782d8a12b.htm)</u> (Registration No. 001-38583), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on July 12, 2018, including any amendments or reports filed for the purpose of updating such description.

In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed "filed" with the SEC. Under no circumstances shall any information furnished under Item 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

****

------

**Item 8. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **<u>Incorporated by Reference</u>** | **<u>Incorporated by Reference</u>** | **<u>Incorporated by Reference</u>** | **<u>Incorporated by Reference</u>** | |
| **Exhibit**<br>**<u>Number</u>** | **<u>Description</u>** | **<u>Form</u>** | **<u>Exhibit</u>** | **<u>Date Filed</u>** | **<u>File Number</u>** | **Filed**<br>**<u>Herewith</u>** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1658247/000119312518222517/d530292dex31.htm)</u> | 8-K | 3.1 | 7/20/2018 | 001-38583 |  |
| 3.2 | <u>[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1658247/000095017023069747/crnx-ex3_1.htm)</u> | 8-K | 3.1 | 12/12/2023 | 001-38583 |  |
| 4.1 | <u>[Specimen stock certificate evidencing the shares of common stock](https://www.sec.gov/Archives/edgar/data/1658247/000119312518214116/d588296dex41.htm)</u> | S-1/A | 4.1 | 7/9/2018 | 333-225824 |  |
| 5.1 | <u>[Opinion of Morrison & Foerster LLP](opinionofmorrisonfoersterl.htm)</u> |  |  |  |  | X |
| 10.1 | <u>[Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1658247/000119312518214116/d588296dex103.htm)</u> | S-1/A | 10.3 | 7/9/2018 | 333-225824 |  |
| 10.2 | <u>[Form of Stock Option Agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1658247/000119312518214116/d588296dex104.htm)</u> | S-1/A | 10.4 | 7/9/2018 | 333-225824 |  |
| 10.3 | <u>[Form of Restricted Stock Unit Agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1658247/000095017022005050/crnx-ex10_5.htm)</u> | 10-K | 10.5 | 3/30/2022 | 001-38583 |  |
| 23.1 | <u>[Consent of Morrison & Foerster LLP (included in Exhibit 5.1)](opinionofmorrisonfoersterl.htm)</u> |  |  |  |  | X |
| 23.2 | <u>[Consent of BDO USA, P.C., independent registered public accounting firm](consentofbdousapcindepende.htm)</u> |  |  |  |  | X |
| 24.1 | <u>[Power of Attorney (included in the signature page to this Registration Statement)](#if4b57f8d014c4515b59b78538744dc74_1)</u> |  |  |  |  | X |
| 107 | <u>[Filing Fee Table](exfilingfees.htm)</u> |  |  |  |  | X |

---

****

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 26, 2026.

---

| | |
|:---|:---|
| **CRINETICS PHARMACEUTICALS, INC.** | **CRINETICS PHARMACEUTICALS, INC.** |
| By: | /s/ R. Scott Struthers, Ph.D. |
| Name: | R. Scott Struthers, Ph.D. |
| Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints R. Scott Struthers, Ph.D. and Tobin Schilke, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ R. Scott Struthers, Ph.D. | President, Chief Executive Officer and Director | February 26, 2026 |
| **R. Scott Struthers, Ph.D.** | (principal executive officer) |  |
| /s/ Tobin Schilke | Chief Financial Officer | February 26, 2026 |
| **Tobin Schilke** | (principal financial and accounting officer) |  |
| /s/ Wendell Wierenga, Ph.D. | Chairman of the Board of Directors | February 26, 2026 |
| **Wendell Wierenga, Ph.D.** |  |  |
| /s/ Camille Bedrosian, M.D. | Director | February 26, 2026 |
| **Camille Bedrosian, M.D.** |  |  |
| /s/ Caren Deardorf | Director | February 26, 2026 |
| **Caren Deardorf** |  |  |
| /s/ Matthew K. Fust | Director | February 26, 2026 |
| **Matthew K. Fust** |  |  |
| /s/ Weston Nichols, Ph.D. | Director | February 26, 2026 |
| **Weston Nichols, Ph.D.** |  |  |
| /s/ Stephanie Okey | Director | February 26, 2026 |
| **Stephanie Okey** |  |  |
| /s/ Rogério Vivaldi Coelho, M.D. | Director | February 26, 2026 |
| **Rogério Vivaldi Coelho, M.D.** |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Crinetics Pharmaceuticals, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.001 par value | Other | 4778774 | $43.25 | $206681975.50 | 0.0001381 | $28542.78 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $206681975.50  |  | $28542.78  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $28542.78  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> The amount registered represents additional shares of the Registrant's common stock that became available for issuance under the Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan (the "2018 Plan"), pursuant to the evergreen provision of the 2018 Plan. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also registers an indeterminate number of additional shares that may be issued pursuant to the 2018 Plan as a result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. The proposed maximum offering price per share and proposed maximum aggregate offering price for the shares of the common stock covered by this Registration Statement have been estimated in accordance with Rule 457(c) and 457(h) solely for the purpose of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Global Select Market on February 19, 2026, which date is within five business days prior to filing this Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | | |
|:---|:---|:---|
| ![mofo.jpg](mofo.jpg) | 2100 L STREET, NW | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | SUITE 900 | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | WASHINGTON | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | DC 20037 | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | TELEPHONE: 202.887.1500 | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | FACSIMILE: 202.887.0763 | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |
| ![mofo.jpg](mofo.jpg) | WWW.MOFO.COM | MORRISON FOERSTER LLP<br>AUSTIN, BEIJING, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI,<br>NEW YORK, PALO ALTO, SAN DIEGO,<br>SAN FRANCISCO, SHANGHAI, SINGAPORE,<br>TOKYO, WASHINGTON, D.C. |

---

February 26, 2026

Board of Directors

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard

San Diego, California 92121

Re: <u>Registration Statement on Form S-8</u> 

Ladies and Gentlemen:

We are acting as counsel to Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), in connection with its registration statement on Form S-8 (the "Registration Statement"), filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act"), relating to the proposed offering of up to 4,778,774 shares (the "Shares") of the Company's common stock, par value $0.001 per share, all of which Shares may be issued pursuant to awards under the Company's 2018 Incentive Award Plan (the "Plan").

As counsel for the Company, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion, and we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization, issuance and sale of the Shares. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the originals of all documents submitted to us as copies. For the purpose of the opinion rendered below, we have assumed that in connection with the issuance of the Shares, the Company will receive consideration in an amount not less than the aggregate par value of the Shares covered by each such issuance. This opinion letter is given, and all statements herein are made, in the context of the foregoing.

The opinion expressed herein is limited to the General Corporation Law of the State of Delaware, the Delaware Constitution and reported judicial decisions interpreting those laws, each as currently in effect.

Based upon and subject to the foregoing, it is our opinion that following (i) effectiveness of the Registration Statement, (ii) issuance of the Shares pursuant to the terms of the Plan, and (iii) receipt by the Company of the consideration for the Shares specified in the applicable resolutions of the Board of Directors or a duly authorized committee thereof and the Plan, the Shares will be validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement, and we consent to the reference of our name wherever appearing in the Registration Statement and any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Morrison & Foerster LLP

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We hereby consent to the incorporation by reference in this Registration Statement of our reports dated February 26, 2026, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, of Crinetics Pharmaceuticals, Inc. (the Company) appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ BDO USA, P.C.

San Diego, California

February 26, 2026

<br>